Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NYSE:NVTA

Invitae (NVTA) Stock Price, News & Analysis

Invitae logo

About Invitae Stock (NYSE:NVTA)

Key Stats

Today's Range
$0.0003
$0.0003
50-Day Range
N/A
52-Week Range
$0.02
$0.02
Volume
75 shs
Average Volume
23.72 million shs
Market Capitalization
$80,103.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Stock News Headlines

[EXPOSED] Little-known Bitcoin “Loophole”
I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free…
Labcorp to acquire Invitae assets for $239 million
Labcorp wins $239M bid for bankrupt Invitae
See More Headlines

NVTA Stock Analysis - Frequently Asked Questions

Invitae Co. (NYSE:NVTA) issued its quarterly earnings results on Tuesday, May, 9th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.04. The firm's quarterly revenue was down 5.1% on a year-over-year basis.

Invitae (NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Invitae investors own include NVIDIA (NVDA), Block (SQ), Tesla (TSLA), Meta Platforms (META), CrowdStrike (CRWD), Teladoc Health (TDOC) and PayPal (PYPL).

Company Calendar

Last Earnings
5/09/2023
Today
1/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Fax
N/A
Employees
1,700
Year Founded
N/A

Profitability

Net Income
$-3,106,290,000.00
Net Margins
-299.14%
Pretax Margin
-301.93%

Debt

Sales & Book Value

Annual Sales
$481.58 million
Book Value
$0.42 per share

Miscellaneous

Free Float
284,373,000
Market Cap
$80,103.00
Optionable
Optionable
Beta
1.59

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NYSE:NVTA) was last updated on 1/7/2025 by MarketBeat.com Staff
From Our Partners